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Big Data Saving Lives?*James V. Freeman, MD, MPH, MS,y Leslie Saxon, MDzR emote monitoring (RM) of cardiac implant-able devices now enables daily monitoringand notiﬁcation of device function and pa-
tient clinical status. Past guideline recommendations
have endorsed in-person follow-up of device patients
or RM every 3 to 6 months (1–3), but RM offers a
simpler alternative, which surveys have shown
patients prefer and physicians ﬁnd straightforward
to use (4,5). Large observational studies using data
from RM follow-up databases of device manufac-
turers, involving >500,000 patients, have evaluated
whether RM has a substantial impact on clinical out-
comes including survival. These studies consistently
show that RM is associated with a survival beneﬁt
compared with periodic in-person device follow-up.
Smaller randomized clinical trials have shown less
beneﬁt or no signiﬁcant survival difference.SEE PAGES 2591 AND 2601In this issue of the Journal, 2 studies shed con-
siderable light on this important knowledge gap.
Varma et al. (6) report ﬁndings from their observa-
tional cohort study of 269,471 patients implanted
with pacemakers (PMs), implantable cardioverter-
deﬁbrillators (ICDs), and cardiac resynchronization
therapy PM/deﬁbrillators (CRT-P/-D) with RM capa-
bility (St. Jude Medical, Inc., Sylmar, California),*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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consulting fees from Medtronic, Inc.comparing outcomes in those who received only
in-person follow-up with those who used RM. This
study has several important ﬁndings. First, more than
one-half (53%) of patients implanted with RM-capable
devices never used the RM functionality. Second,
there was a survival advantage for those patients
who used RM, and increased use of RM with weekly
transmissions more than 75% of the time was associ-
ated with a greater survival advantage compared
with those who used RM less frequently. Finally,
these results were consistent across all device types
including PMs, ICDs, and CRT devices.
These ﬁndings are very consistent with those
from the ALTITUDE (7) observational cohort study
of 69,556 patients implanted with ICD and CRT-D
devices (Boston Scientiﬁc Corporation, Natick, Mas-
sachusetts). This earlier study reported a 50%
reduction in mortality (ICD hazard ratio: 0.56; CRT-D
hazard ratio: 0.45; p < 0.0001) in those patients who
used RM compared with those who had only in-
person follow-up. Varma et al. (6) extend the results
of the ALTITUDE study by showing that higher use
of RM was associated with improved survival in
a dose–response relationship. This ﬁnding may be
particularly important in helping to understand why
some previous studies with less frequent RM did
not have a substantial impact on outcomes, such as
survival. There may be a threshold of RM frequency
beyond which outcomes are substantively impacted,
with greater effect as RM frequency increases. Varma
et al. (6) also extend the ALTITUDE results by
demonstrating a survival beneﬁt with RM-capable
PMs with an effect size consistent with that for
ICDs. This is important in that it may provide some
insight into the putative mechanisms by which RM
patients have improved outcomes. PM patients are
generally less ill than ICD patients and the devices
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capable of conferring a survival advantage. The au-
thors hypothesize that the consistent effect size be-
tween PMs and ICDs suggests that identiﬁcation and
treatment of atrial arrhythmias, high-rate episodes,
or changes in pacing and lead parameters may
mediate the improved survival with RM devices.
However, RM may also simply intensify physician
and patient engagement and communication more
generally, apart from speciﬁc device functionality.
The ALTITUDE study and the study by Varma
et al. (6) are similar with regard to their observa-
tional study design. These studies have the great
advantage of including very large patient cohorts
that are highly representative of the larger popula-
tion of U.S. device recipients and, therefore, gener-
alizable relative to the more rareﬁed and selected
clinical trial populations. These cohort studies are
also similar in their limitations, including the fact
that both had only modest data on baseline clinical
characteristics that would have allowed for compre-
hensive adjustment for clinical differences between
patients using RM and those treated with in-person
visits only. RM use may serve as a marker for pa-
tients who are more fastidious about their health and
physicians who are more intensive with their care,
rather than a true mediator of improved outcomes.
Alternatively, sicker patients may be referred for
RM to allow closer follow-up and, in this scenario,
RM-selected patients would be expected to have a
survival disadvantage. The ALTITUDE authors per-
formed a sensitivity analysis, which showed that
baseline risk that had not been accounted for in the
analysis would need to be 5 times greater in the
patients not using RM to make the reported survival
beneﬁt nonsigniﬁcant, suggesting that the associa-
tion between RM and survival is likely robust. All the
patients evaluated by Varma et al. (6) in the present
study were implanted with RM-capable devices,
which should at least partially address the concern of
confounding introduced by baseline patient differ-
ences. In addition, another observational cohort
study (8) of 37,742 patients implanted with ICD and
CRT-D devices (Boston Scientiﬁc) was recently pre-
sented and linked device RM data from ALTITUDE
to detailed patient characteristics from National
Cardiovascular Data Registry ICD Registry for im-
proved patient characteristic analytic adjustment.
This study showed an improvement in patient sur-
vival consistent with the previous observational
studies. Nonetheless, it remains possible that resid-
ual confounding factors account for some of the
reported association between RM and improved
outcomes in these observational cohort studies.Although a large prospective randomized clinical
trial would control for the most likely confounding
factors, a new trial is unlikely to be undertaken given
that the technology for RM now exists in all devices
at minimal or no extra cost.
Previous randomized controlled trials evaluating an
association between RM and patient outcomes have
been relatively small and have shown a beneﬁt in
some studies but no signiﬁcant difference in others.
One of the largest and the most contemporary of
these studies was the IN-TIME (Inﬂuence of Home
Monitoring on Mortality and Morbidity in Heart Fail-
ure Patients with Impaired Left Ventricular Function)
trial (9), which included 664 ICD and CRT-D patients
randomly assigned to either automatic, daily RM in
addition to standard care or standard care alone. The
primary outcome measure was a composite clinical
score combining all-cause death, overnight hospital
admission for heart failure, change in New York Heart
Association class, and change in patient global self-
assessment. At 1 year, 63 (18.9%) of 333 patients in
the RM group compared with 90 (27.2%) of 331 in the
control group (p ¼ 0.013) had worsened composite
scores (odds ratio: 0.63; 95% conﬁdence interval:
0.43 to 0.90) and 10 versus 27 patients who died dur-
ing follow-up. These contemporary data seem to
conﬁrm the observational study ﬁndings, but were
discordant with several previous randomized studies.
In an effort to synthesize the currently available
randomized controlled trial data and make sense of
the disparate results, Parthiban et al. (10) also report
in this issue of the Journal a systematic review
and meta-analysis of 9 randomized controlled trials
comparing RM with in-person follow-up in patients
with cardiac implantable devices. They showed
that across all 9 studies, including approximately
6,500 patients, there was no signiﬁcant difference in
all-cause mortality, cardiovascular mortality, hospi-
talization, or ICD shock, although there was a reduc-
tion in the risk of inappropriate shock and the time
required to detect a clinical event or reach a clinical
decision. However, importantly, in the 3 trials
(including IN-TIME) that used daily RM transmission,
there was a signiﬁcant reduction in all-cause mortal-
ity, suggesting that the beneﬁts of RM can only be
fully realized with more frequent RM data trans-
mission. Moreover, the mean follow-up interval in
the randomized trials was signiﬁcantly less than in
the observational studies that continue to see beneﬁt
out to 5 years of follow-up.
Thus, the observational and randomized trial pub-
lished data seem to consistently demonstrate that
RM of patients with cardiac implantable devices is
safe, with outcomes at least comparable with those
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2613treated with in-person follow-up alone. Furthermore,
contemporary studies suggest that with more frequent
RM transmission (daily in the most recent studies)
outcomes may be superior, including a possible sur-
vival advantage over periodic in-person device eval-
uation. In light of these results, the consistent ﬁnding
in the observational published data showing that RM
use remains poor in clinical practice suggests that ef-
forts to change treatment patterns through more
aggressive use of guideline recommendations and
continuing medical education should be undertaken
at this point. Additionally, research must be con-
ducted to better understand patient- and physician-
level impediments to adopting RM and methods to
address these barriers. RM and remote patient
engagement represent a cultural shift in the tradi-
tional medical care model and allow for a more ﬂuid
and continuous patient care paradigm that many
physicians may not feel comfortable integrating
into their practice behaviors. Nonetheless, digitally
enabled remote diagnostics provide an incredible op-
portunity to use the efﬁciency of wireless network
data collection and analytics to engage and beneﬁt the
implanted device population and realize more value
from the device itself.
Finally, the cardiac implantable device and re-
search communities should continue to investigateways of optimizing and improving RM and the timely
use of “big data” to improve clinical outcomes. We
need to improve artiﬁcial intelligence methods for
automating triage of RM data that would minimize
the need for practitioner review and prioritize
more clinically important data to facilitate rapid
clinical decision support and timely intervention.
Data delivery directly to patients through an alert
or Internet-based system could be developed that
enables patients to better understand their clinical
status and allows them to respond in a timely fashion;
independently when appropriate, or with clinician
input when necessary. RM data can be integrated
with electronic medical records to ease clinician
administrative burden and minimize the risk of data
being lost or inaccurately recorded. Cardiac implant-
able devices are in the vanguard of the personal
“big data” revolution; it is imperative that we con-
tinue to improve the quality and use of the data
they generate to best meet the needs and optimize
the outcomes of patients and enable physicians to
practice most efﬁciently.
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